DNA methylation – a crucial role in cancer development
25 Apr 2024
Cervical cancer screening is evolving continuously, high risk HPV testing now detects more women with cervical pre-cancer. However, identifying who needs immediate treatment still proves challenging, leading to many women undergoing invasive procedures such as a colposcopy. Fujirebio highlights DNA methylation as playing a crucial role in cancer development. Explore why DNA methylation is a pre-cursor for cancer, how this can be tested, and the benefits compared to invasive procedures.
About the company
Fujirebio
Fujirebio is global R&D-driven company constantly developing new in vitro diagnostics testing technologies and unique biomarkers with high clinical value. Our group mission is to create new value in healthcare and thereby contribute to human health and the future of medical care. Our global teams located in Japan, Asia, Europe, and the US focus on delivering products with the highest quality standards to our customers and partners. We value CDMO partnerships with many of the world’s leading diagnostic companies, sharing knowledge, capabilities, and critical materials to supply, develop, or manufacture diagnostic solutions on a wide variety of platforms.